Intensive Intervention Improves Outcomes for Chronic Obstructive Pulmonary Disease Patients: A Medical Consortium-Based Management

Table 2

Differences in clinical characteristics between subjects of the control group and the management group after intervention.

Variable	Intervention for 6 months			Intervention for 12 months
	Control group; (n = 147)	Management group; (n = 141)		Control group; (n = 147)	Management group; (n = 141)
Smoker, n (%)	68 (46)	53 (38)	0.137	63 (43)	34 (24)	0.000
Pulmonary rehabilitation	78 (53)	92 (65)	0.036	77 (82)	97 (69)	0.004
Pursed-lips breathing	35 (24)	73 (52)	0.000	42 (29)	81 (57)	0.000
Average oxygen use per day (hours)	1.22 ± 2.68	2.84 ± 4	0.000	1.31 ± 2.72	2.99 ± 4.21	0.000
Medication regularity	62 (42)	97 (69)	0.000	51 (35)	113 (80)	0.000
Barthel ADL index (≥60)	84 (57)	60 (43)	0.003	93 (64)	36 (26)	0.000
mMRC grades (≥2), n (%)	144 (98)	132 (93)	0.037	140 (95)	127 (90)	0.000
CAT	17.25 ± 4.52	15.62 ± 4.18	0.001	18.06 ± 4.62	14.45 ± 4.04	0.000
Pulmonary function
FEV1/FVC (%)	54.12 ± 8.95	53.54 ± 8.79	0.561	53.56 ± 9.4	55.28 ± 8.5	0.185
FVC/% predicted	59.95 ± 17.58	58.58 ± 16.31	0.537	56.88 ± 16.83	61.96 ± 16.93	0.013
FEV1/% predicted	42.84 ± 16.98	40.94 ± 14.99	0.497	40.27 ± 16.21	44.76 ± 15.9	0.011
MEF25	1.39 ± 1.1	1.27 ± 0.97	0.603	1.34 ± 1.05	1.35 ± 0.99	0.329
MEF50	0.73 ± 0.58	0.7 ± 0.55	0.806	0.7 ± 0.56	0.72 ± 0.52	0.111
MEF75	0.36 ± 0.24	0.33 ± 0.2	0.442	0.34 ± 0.23	0.34 ± 0.19	0.023
GOLD-ABCD
A, n (%)	2 (1.36)	5 (3.55)	0.274	3 (2.04)	11 (7.80)	0.028
B, n (%)	49 (33.33)	37(26.24)	0.2	40 (27.21)	38 (26.95)	0.999
C, n (%)	1 (0.68)	5(3.55)	0.114	4 (2.72)	4 (2.84)	0.999
D, n (%)	95 (64.63)	94 (66.67)	0.804	100 (68.03)	88 (62.41)	0.325